- Conditions
- Recurrent Malignant Glioma
- Interventions
- OKN-007
- Drug
- Lead sponsor
- Oblato, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Glioblastoma
- Interventions
- OKN 007, Temozolomide, Photon/Proton IMRT
- Drug · Radiation
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
- Interventions
- Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID, High-dose OKN-007, TID
- Drug
- Lead sponsor
- Oblato, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Louisville, Kentucky • Winston-Salem, North Carolina + 1 more
- Conditions
- Recurrent Malignant Glioma, Brain Glioblastoma
- Interventions
- OKN-007, Temozolomide (TMZ)
- Drug
- Lead sponsor
- Oblato, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California + 10 more
- Conditions
- Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
- Interventions
- OKN-007
- Drug
- Lead sponsor
- Oblato, Inc.
- Industry
- Eligibility
- 13 Months to 18 Years
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 6 more